Compare Cassava Sciences Inc (FLNA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Mesoblast Limited — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Mesoblast Limited trades at $19.22 (market cap $2.31B). The key difference: Mesoblast Limited is far larger — about 43.5× Cassava Sciences Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MESO | |
|---|---|---|
Market Cap | $53.14M | $2.31B |
Sector | Health | Technology |
52-Week High | $4.64 | $20.96 |
52-Week Low | $1.09 | $11.35 |
Enterprise Value | -$33.43M | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
